Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accounts Payables: 2014-2024

Historic Accounts Payables for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $25.5 million.

  • Zevra Therapeutics' Accounts Payables fell 54.74% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 54.74%. This contributed to the annual value of $25.5 million for FY2024, which is 10.38% down from last year.
  • Zevra Therapeutics' Accounts Payables amounted to $25.5 million in FY2024, which was down 10.38% from $28.4 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Accounts Payables peaked at $28.4 million during FY2023, and registered a low of $3.0 million during FY2021.
  • For the 3-year period, Zevra Therapeutics' Accounts Payables averaged around $20.0 million, with its median value being $25.5 million (2024).
  • As far as peak fluctuations go, Zevra Therapeutics' Accounts Payables tumbled by 54.30% in 2021, and later soared by 360.41% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Accounts Payables (Yearly) stood at $6.6 million in 2020, then tumbled by 54.30% to $3.0 million in 2021, then skyrocketed by 103.06% to $6.2 million in 2022, then spiked by 360.41% to $28.4 million in 2023, then fell by 10.38% to $25.5 million in 2024.